Lexicon Pharmaceuticals

LXRX · NASDAQ

$1.58+$0.03 (+1.94%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $1.55

LXRX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $4.64 (+193.5% upside)

Low: $2.02
Now: $1.58
High: $8.40

Upgrades and downgrades

The latest rating actions, newest first

LXRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Sep 28, 2026	Initiates	Overweight	$8.00	39%
Citigroup	May 11, 2026	Maintains	Buy	$2.30 → $3.10	42%
HC Wainwright & Co.	Mar 23, 2026	Maintains	Buy	$6.00	40%
Citigroup	Mar 10, 2026	Maintains	Buy	$2.10 → $2.30	42%
HC Wainwright & Co.	Mar 5, 2026	Maintains	Buy	$4.00 → $6.00	40%

The case for and against

Updated Dec 15, 2025

Bull case

Lexicon Pharmaceuticals is advancing its research and development programs, particularly with drug candidates LX9211 and LX9851, which target significant health issues such as diabetic peripheral neuropathic pain and obesity, respectively. The company is expected to strengthen its cash position through partnerships, notably with Novo, enhancing its financial stability and capacity for future growth. The anticipated Phase 2 data for LX9211, expected in the first quarter of 2025, suggests ongoing progress and potential value creation for the company.

Bear case

Lexicon Pharmaceuticals Inc faces significant challenges that could negatively impact its stock outlook, primarily related to clinical trial results and funding issues. The excerpts highlight concerns about failed or inconclusive clinical trials, which could severely hinder the company's ability to advance its drug candidates like LX9211 and LX9851. Furthermore, the potential for dilutive capital raises raises additional red flags regarding the company's financial stability and market valuation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.